Abstract: The present disclosure relates to a thermoplastic polyurethane composition for injection molding and a method for manufacturing the same. Specifically, the thermoplastic polyurethane composition includes 0.5% by weight to 10.0% by weight of a sulfonate diol, 13% by weight to 60% by weight of an isocyanate, 30% by weight to 70% by weight of an ether-containing polyester polyol, and 5% by weight to 40% by weight of a chain extender.

Abstract: A display apparatus includes a base substrate, a light emitting structure disposed on the base substrate, and a thin film encapsulation layer disposed on the light emitting structure and including at least one inorganic layer and at least one organic layer. The at least one inorganic layer includes a high density layer having a density of greater than or equal to about 2.0 g/cm3 and a low density layer having a density of less than about 2.0 g/cm3. The high density layer and the low density layer are in contact with each other.

Abstract: A wireless communication method and apparatus in a wireless local area network (WLAN) system are disclosed. A wireless communication method according to one embodiment may include generating a high-efficiency Wi-Fi (HEW) frame including at least one of an HEW-SIG-A field and an HEW-SIG-B field which include channel information for communications according to an Orthogonal Frequency-Division Multiple Access (OFDMA) mode, and transmitting the generated HEW frame to a reception apparatus.

Abstract: The present disclosure relates to a polycarbonate resin composition, and more particularly, to a polycarbonate resin composition containing 90 wt % to 99 wt % of a polycarbonate resin, 0.3 wt % to 0.7 wt % of an anthraquinone-based black dye, and 0.2 wt % to 1.0 wt % of an acrylic polymeric chain extender, and a molded article containing the same.

Abstract: A monoclonal antibody or an antigen-binding fragment thereof according to an embodiment of the present invention can bind to lymphocyte-activation gene 3 (LAG-3) including a heavy chain variable region and a light chain variable region and inhibit the activity thereof. Thus it is expected to be useful for the development of immunotherapeutic agents for various disorders that are associated with LAG-3.

Abstract: A color conversion substrate and a display device are provided. The color conversion substrate includes a base substrate, a first color filter and a second color filter disposed on a surface of the base substrate, a first partition layer disposed between the first color filter and the second color filter, a second partition layer disposed on the first partition layer, a first wavelength conversion pattern disposed on the first color filter and a second wavelength conversion pattern disposed on the second color filter, wherein the first partition layer includes a first lower surface disposed on the first color filter and a second lower surface disposed on the second color filter.

Abstract: A semiconductor device and a method of manufacturing a semiconductor device, the device including gate structures on a substrate; source/drain layers on portions of the substrate that are adjacent the gate structures, respectively; first contact plugs contacting upper surfaces of the source/drain layers, respectively; a second contact plug contacting one of the gate structures, a sidewall of the second contact plug being covered by an insulating spacer; and a third contact plug commonly contacting an upper surface of at least one of the gate structures and at least one of the first contact plugs, at least a portion of a sidewall of the third contact plug not being covered by an insulating spacer.

Abstract: The present invention relates to a fusion protein comprising a SARS-CoV-2-derived receptor-binding domain and a nucleocapsid protein, and the use thereof. The fusion protein comprising a coronavirus-derived receptor-binding domain and a nucleocapsid protein is highly applicable to a multivalent vaccine composition having greatly improved in-vivo half-life and remarkably superior efficacy compared to an immunogenic composition comprising only a receptor-binding domain. In particular, the fusion protein can greatly improve the titer of the coronavirus-specific antibody formation and T-cell immune response, and is thus useful for the prevention and treatment of coronaviruses comprising SARS-CoV-2.

Abstract: Provided are a novel boron-containing compound and an electrolyte solution additive for a secondary battery including the same. The electrolyte solution for a secondary battery provided in one embodiment includes the novel boron-containing compound, thereby suppressing the decomposition of an electrolyte solution to improve the capacity and the life characteristics of a battery.

Abstract: The present invention provides a pharmaceutical composition for the prevention or treatment of glaucoma, wherein the pharmaceutical composition includes angiogenin or a fragment thereof as an active ingredient. Angiogenin or a fragment thereof according to the present invention activates aqueous humor outflow due to NO generation increase, Schlemm's canal expansion, and intercellular interval widening, thereby reducing intraocular pressure. Accordingly, angiogenin and a fragment may be useful for the prevention and treatment of glaucoma.

Abstract: A toothbrush having replaceable brush heads includes a plurality of brush heads including a pad provided on both lateral sides thereof with mounting protrusions, and a plurality of brush hairs provided on a top surface of the pad, and a brush handle body integrally extending from the brush head, including a mounting head part formed at a front end thereof to fixedly mount the pad of the brush head thereon, and a gripping rod having a receiving space part open or closed by a cap to receive the brush heads into an opposite side to the mounting head part, thereby easily storing the brush heads without the movement, securely and fixedly mounting the brush heads without the separation from the toothbrush even in the brushing of teeth, and simply replacing the brush head with new one according to occasions and using the brush head.

Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.

Abstract: Provided is a pharmaceutical composition for treating corneal endothelium wounds, the composition including angiogenin as an effective ingredient. The present invention relates to a new topical therapeutic use of angiogenin for treatment of corneal endothelium wounds, wherein the angiogenin that is generally known to be involved in angiogenesis activates a PI3K/Akt/eNOS pathway thereof in ocular corneal endothelium to increase migration and proliferation of corneal endothelial cells that are not capable of self-proliferation and to promote prevention and treatment of corneal endothelial cell wounds.

Abstract: Provided is a pharmaceutical composition for treating corneal endothelium wounds, the composition including angiogenin as an effective ingredient. The present invention relates to a new topical therapeutic use of angiogenin for treatment of corneal endothelium wounds, wherein the angiogenin that is generally known to be involved in angiogenesis activates a PI3K/Akt/eNOS pathway thereof in ocular corneal endothelium to increase migration and proliferation of corneal endothelial cells that are not capable of self-proliferation and to promote prevention and treatment of corneal endothelial cell wounds.

Abstract: The present invention provides a pharmaceutical composition for the prevention or treatment of glaucoma, wherein the pharmaceutical composition includes angiogenin or a fragment thereof as an active ingredient. Angiogenin or a fragment thereof according to the present invention activates aqueous humor outflow due to NO generation increase, Schlemm's canal expansion, and intercellular interval widening, thereby reducing intraocular pressure. Accordingly, angiogenin and a fragment may be useful for the prevention and treatment of glaucoma.

Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.

Abstract: The present invention relates to a use of Substance-P for the manufacture of a medicament for mobilization or proliferation of Mesenchymal stem cells (MSCs) from the bone marrow, or facilitating said mobilization or proliferation, and use of Substance-P for the manufacture of a medicament for wound-healing or facilitating wound-healing.

Abstract: Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins.

Abstract: The present invention relates to a method for preparing a contact lens-shaped amniotic dressing and a contact lens-shaped amniotic dressing prepared therefrom for treating ocular surface diseases, which does not require the use of sutures or an adhesion material. The inventive contact lens-shaped amniotic dressing is capable of solving the problems associated with suturing an amniotic membrane, e.g., highly delicate surgical techniques of suturing, long surgery time, stitch abscess, granuloma formation, tissue necrosis, and discomfort of patients; and the problems associated with the use of a support, e.g., the elimination of the support by eye blinking, breaking of the support, and discomfort.

Abstract: Disclosed herein are bio-markers for diagnosing diabetic retinopathy, a use of proteins, whose expression level down-regulated or up-regulated in the tears of a non-proliferative diabetic retinopathy (NPDR) patient, as bio-markers for diagnosing diabetic retinopathy, and a composition and kit for diagnosing diabetic retinopathy comprising antibodies against said proteins.